Aude Servais

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6303134/publications.pdf

Version: 2024-02-01

46 papers	1,794 citations	430874 18 h-index	276875 41 g-index
46 all docs	46 docs citations	46 times ranked	1942 citing authors

#	Article	IF	Citations
1	FDX2 and ISCU Gene Variations Lead to Rhabdomyolysis With Distinct Severity and Iron Regulation. Neurology: Genetics, 2022, 8, e648.	1.9	4
2	COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. Nephrology Dialysis Transplantation, 2022, 37, 1357-1365.	0.7	17
3	Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis. BMC Nephrology, 2022, 23, 67.	1.8	3
4	Central Nervous System Complications in Cystinosis: The Role of Neuroimaging. Cells, 2022, 11, 682.	4.1	3
5	Postauthorization safety study of betaine anhydrous. Journal of Inherited Metabolic Disease, 2022, 45, 719-733.	3.6	5
6	Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients. CKJ: Clinical Kidney Journal, 2022, 15, 1675-1684.	2.9	9
7	Home Blood Pressure Measurement and Self-Interpretation of Blood Pressure Readings During Pregnancy: Hy-Result e-Health Prospective Study. Vascular Health and Risk Management, 2022, Volume 18, 277-287.	2.3	3
8	Idiopathic nephrotic syndrome relapse following COVID-19 vaccination: a series of 25 cases. CKJ: Clinical Kidney Journal, 2022, 15, 1574-1582.	2.9	7
9	Intravenous administration of a branched-chain amino-acid-free solution in children and adults with acute decompensation of maple syrup urine disease: a prospective multicentre observational study. Orphanet Journal of Rare Diseases, 2022, 17, 202.	2.7	1
10	Pregnancy in cystinosis patients with chronic kidney disease: A European case series. Journal of Inherited Metabolic Disease, 2022, 45, 963-968.	3.6	3
11	Cystathionine Î²â€synthase deficiency in the <scp>Eâ€HOD registryâ€part</scp> I: pyridoxine responsiveness as a determinant of biochemical and clinical phenotype at diagnosis. Journal of Inherited Metabolic Disease, 2021, 44, 677-692.	3.6	20
12	Cystinuria: clinical practice recommendation. Kidney International, 2021, 99, 48-58.	5.2	58
13	Enteral tube feeding in patients receiving dietary treatment for metabolic diseases: A retrospective analysis in a large French cohort. Molecular Genetics and Metabolism Reports, 2021, 26, 100655.	1.1	7
14	Long-term renal outcome in methylmalonic acidemia in adolescents and adults. Orphanet Journal of Rare Diseases, 2021, 16, 220.	2.7	7
15	The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. Orphanet Journal of Rare Diseases, 2021, 16, 251.	2.7	26
16	An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis. Kidney International, 2021, 100, 1112-1123.	5.2	31
17	Central nervous system complications in adult cystinosis patients. Journal of Inherited Metabolic Disease, 2020, 43, 348-356.	3.6	14
18	Longâ€term outcome of methylmalonic aciduria after kidney, liver, or combined liverâ€kidney transplantation: The French experience. Journal of Inherited Metabolic Disease, 2020, 43, 234-243.	3.6	20

#	Article	IF	Citations
19	The Case | Atrophic kidney and ocular abnormalities. Kidney International, 2020, 98, 1059-1060.	5.2	2
20	Neonatal factors related to survival and intellectual and developmental outcome of patients with early-onset urea cycle disorders. Molecular Genetics and Metabolism, 2020, 130, 110-117.	1.1	4
21	Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort. Molecular Genetics and Metabolism Reports, 2020, 23, 100581.	1.1	12
22	Clinical and histological differences between adults and children in new onset IgA nephropathy. Pediatric Nephrology, 2020, 35, 1897-1905.	1.7	20
23	Management of bone disease in cystinosis: Statement from an international conference. Journal of Inherited Metabolic Disease, 2019, 42, 1019-1029.	3.6	39
24	APOL1 risk genotype in Europe: Data in patients with focal segmental glomerulosclerosis and after renal transplantation. Nephrologie Et Therapeutique, 2019, 15, S85-S89.	0.5	2
25	Phenotype, treatment practice and outcome in the cobalaminâ€dependent remethylation disorders and MTHFR deficiency: Data from the Eâ€HOD registry. Journal of Inherited Metabolic Disease, 2019, 42, 333-352.	3.6	53
26	Comparison of Postdonation Kidney Function Between Caucasian Donors and Low-risk APOL1 Genotype Living Kidney Donors of African Ancestry. Transplantation, 2018, 102, e462-e463.	1.0	5
27	Effects of L-Carnitine on Mineral Metabolism in the Multicentre, Randomized, Double Blind, Placebo-Controlled CARNIDIAL Trial. American Journal of Nephrology, 2018, 48, 349-356.	3.1	8
28	Identification of genetic causes for sporadic steroid-resistant nephrotic syndrome in adults. Kidney International, 2018, 94, 1013-1022.	5.2	51
29	The Case | A 69-year-old man with purpura and acute renal failure. Kidney International, 2018, 94, 435-436.	5.2	0
30	Update on Lysinuric Protein Intolerance, a Multi-faceted Disease Retrospective cohort analysis from birth to adulthood. Orphanet Journal of Rare Diseases, 2017, 12, 3.	2.7	78
31	Renal involvement in lysinuric protein intolerance: contribution of pathology to assessment of heterogeneity of renal lesions. Human Pathology, 2017, 62, 160-169.	2.0	18
32	Longâ€term metabolic followâ€up and clinical outcome of 35 patients with maple syrup urine disease. Journal of Inherited Metabolic Disease, 2017, 40, 783-792.	3.6	25
33	Controversies and research agenda in nephropathic cystinosis: conclusions from a â€œKidney Disease: Improving Global Outcomesâ€•(KDIGO) Controversies Conference. Kidney International, 2016, 89, 1192-1203.	5.2	52
34	Excellent long-term outcome of renal transplantation in cystinosis patients. Orphanet Journal of Rare Diseases, 2015, 10, 90.	2.7	27
35	The Authors Reply:. Kidney International, 2014, 86, 857-858.	5.2	4
36	Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up. Human Pathology, 2014, 45, 2326-2333.	2.0	15

#	Article	IF	Citations
37	Nephropathic cystinosis: an international consensus document. Nephrology Dialysis Transplantation, 2014, 29, iv87-iv94.	0.7	164
38	Increased risk of solid renal tumors in lithium-treated patients. Kidney International, 2014, 86, 184-190.	5.2	62
39	C3 Glomerulopathy. Contributions To Nephrology, 2013, 181, 185-193.	1.1	28
40	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney International, 2012, 82, 454-464.	5.2	454
41	Heterogeneous pattern of renal disease associated with homozygous Factor H deficiency. Human Pathology, 2011, 42, 1305-1311.	2.0	41
42	Statistical color texture descriptors for histological images analysis. , 2011, , .		19
43	Late-Onset Nephropathic Cystinosis. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 27-35.	4.5	68
44	Quantification of Interstitial Fibrosis by Image Analysis on Routine Renal Biopsy in Patients Receiving Cyclosporine. Transplantation, 2007, 84, 1595-1601.	1.0	44
45	Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. Journal of Medical Genetics, 2006, 44, 193-199.	3.2	259
46	Very longâ€term outcomes in 23 patients with <scp>cblA</scp> type methylmalonic acidemia. Journal of Inherited Metabolic Disease, 0, , .	3.6	2